Innoviva
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Innoviva and other ETFs, options, and stocks.About INVA
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI.
CEOPavel Raifeld
CEOPavel Raifeld
Employees127
Employees127
HeadquartersBurlingame, California
HeadquartersBurlingame, California
Founded1996
Founded1996
Employees127
Employees127
INVA Key Statistics
Market cap1.46B
Market cap1.46B
Price-Earnings ratio14.02
Price-Earnings ratio14.02
Dividend yield—
Dividend yield—
Average volume660.76K
Average volume660.76K
High today—
High today—
Low today—
Low today—
Open price$19.43
Open price$19.43
Volume0.00
Volume0.00
52 Week high$22.76
52 Week high$22.76
52 Week low$16.52
52 Week low$16.52
Stock Snapshot
As of today, Innoviva(INVA) shares are valued at $19.55. The company's market cap stands at 1.46B, with a P/E ratio of 14.02.
Innoviva(INVA) stock opened on 2026-01-21 at $19.43. The price climbed to — and dipped to —.
The Innoviva(INVA)'s current trading volume is 0, compared to an average daily volume of 660.76K.
In the last year, Innoviva(INVA) shares hit a 52-week high of $22.76 and a 52-week low of $16.52.
In the last year, Innoviva(INVA) shares hit a 52-week high of $22.76 and a 52-week low of $16.52.
People also own
Based on the portfolios of people who own INVA. This list is generated using Robinhood data, and it’s not a recommendation.